Non-invasive
prenatal testing Market was valued at USD 26.23 billion in 2013 and
is expected to reach an estimated value of USD 119.51 billion in
2019, growing at a CAGR of 24.2% from 2013 to 2019.
Non-invasive
prenatal testing is increasingly being adopted by high risk pregnant
women for the screening of common fetal chromosomal aneuploidies such
as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau
syndrome (trisomy 13), Turner syndrome (monosomy X) and many others.
The non-invasive nature of these tests, their accuracy and safety
have been the major reasons behind their popularity among
gynecologists and expecting mothers. MaterniT21 was the first NIPT
launched in October 2011, by U.S. based Sequenom, Inc. and since then
has been leading the market with the largest market share. Sources
from Sequenom, Inc. indicate that the company accounts for more than
60% unit share of the high risk pregnancy market in the U.S. Harmony,
verifi, Panorama, NIFTY, PrenaTest and BambniTest are other
commercially available NIPTs for detecting chromosomal abnormalities.
More Detail : http://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html
The exponential growth of the NIPT market is supported by factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). As maternal age is closely associated with the increasing risk of developing a fetus with chromosomal abnormalities, rising maternal age is likely to contribute to the increasing incidence of babies born with chromosomal aneuploidies. According to Down syndrome education (DSE), in the U.S., the incidence rate for Down syndrome is 1 in every 830 child births (around 4,700 annually), while in Europe the incidence rate is 1 in every 920 babies born (around 9,000 annually), indicating a large potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as amniocentesis and chorionic villus sampling (CVS) are associated with the chance of miscarriage, which is the prime reason for their replacement with new non-invasive prenatal tests. These new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and pose no risk of miscarriage.
North
America held the largest share in the global NIPT market in terms of
revenue in 2012, accounting for 64.5% of the total market revenue.
The fact that the major market players are U.S. based along with
relatively high awareness levels in the North American region about
NIPT are the key factors responsible for the region’s leadership
position. In Europe, the market growth largely relies on the
increasing penetration of these U.S. based test developers and the
expected increase in acceptance of these tests. In the Asia-Pacific
market, Japan, Australia, China and India represent the high growth
potential markets. The presence of a large population of women
preferring late pregnancy is likely to act as one of the major growth
drivers in the region. In China, the market is dominated by two local
players, namely, BGI Health and Berry Genomics.
About Us
We
are privileged with highly experienced team of Analysts, Researchers
and Consultants, who use proprietary data sources and various tools
and techniques to gather, and analyze information. Our business
offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact
Transparency
Market Research
90
State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA
- Canada Toll Free 866-552-3453
